Pfizer Buy Pushes Double-Digit Growth For J&J Consumer Product Sales
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson's consumer products sales jumped 48.5 percent to $3.49 billion in the firm's first fiscal quarter since closing its acquisition of Pfizer Consumer Healthcare
You may also be interested in...
J&J, Pfizer Satisfy FTC Conditions To Clear Deal; EC Signs Off
Johnson & Johnson and Pfizer's divestiture of the Zantac, Cortizone, Unisom and Balmex brands satisfies the Federal Trade Commission's anticompetitive complaint about J&J's acquisition of Pfizer's consumer healthcare business
Boehringer Hits Above The Belt With Zantac Purchase
Boehringer Ingelheim looks to expand its therapeutic territory up the GI tract with a $509.5 mil. purchase of U.S. rights to the acid reducer Zantac (ranitidine) from Johnson & Johnson and the Pfizer Consumer Healthcare business
Chattem Acquires “Great Brands” In Wake Of J&J’s Pfizer Purchase
Chattem said its past experience with brands such as Icy Hot and Selsun Blue will make for an easier transition of its newest package acquisition